Erectile Dysfunction Drugs as Potential Therapy for Cognitive Decline: Preclinical and Translational Evidence.
1Section of General Pathology, Department of Experimental Medicine, School of Medical and Pharmacological Sciences, University of Genoa, 16132 Genoa, Italy.
Cells
|October 15, 2025
Summary
Phosphodiesterase type 5 inhibitors (PDE5-Is) used for erectile dysfunction may also improve cognitive function. This review explores their potential benefits for memory and Alzheimer's disease by examining vascular and neuroprotective mechanisms.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Erectile dysfunction (ED) and cognitive decline share common underlying mechanisms, especially in aging individuals.
- These mechanisms include vascular, metabolic, and neurodegenerative pathways.
- Phosphodiesterase type 5 inhibitors (PDE5-Is) are established treatments for ED.
Purpose of the Study:
- To review the potential of PDE5 inhibitors as therapeutic agents for cognitive impairment.
- To synthesize evidence from clinical, preclinical, and mechanistic studies.
- To explore the role of PDE5 inhibitors in learning, memory, and Alzheimer's disease.
Main Methods:
- Literature review of clinical and preclinical studies.
- Analysis of mechanistic data on PDE5 inhibitors.
- Synthesis of research on cognitive function, neuroprotection, and Alzheimer's disease.
Main Results:
- PDE5 inhibitors enhance vascular function by increasing cyclic guanosine monophosphate (cGMP) levels.
- Emerging evidence suggests PDE5 inhibitors may promote neurovascular coupling and synaptic plasticity.
- Potential neuroprotective effects of PDE5 inhibitors are being investigated.
Conclusions:
- PDE5 inhibitors show promise for treating cognitive impairment.
- Further research is warranted to confirm their efficacy in conditions like Alzheimer's disease.
- Targeting PDE5 may offer a novel therapeutic strategy for age-related cognitive decline.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
558
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
558
01:22Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
187
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
187
01:15Drug Dosing: Geriatric Patients
225
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
225
01:30Cognitive Development During Adulthood
772
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
772